Ratio Therapeutics raised $70 million to support radiopharmaceutical trials, marking a continuation of capital investment in radioisotope-driven oncology programs. The Boston biotech’s Series C funding included support from existing investors Duquesne Family Office and Bristol Myers Squibb, along with new backers. In parallel, the market also saw renewed interest in precommercial biotech financing, with Vogenx signaling an intent to raise about $67 million through an IPO. Together, these moves underline that investors remain willing to fund both clinical development execution and early-stage commercialization planning. For the radiopharma and precision oncology ecosystem, the Ratio financing is a direct input to trial capacity—timelines for dose-escalation, imaging validation, and expansion cohort recruitment—while IPO-bound activity reflects continued appetite for pipeline optionality.